Evelo Biosciences Provides Clinical and Business Updates
01. Februar 2023 07:30 ET
|
Evelo Biosciences, Inc.
– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed –– Clear path to registration trials for...
Evelo Biosciences Announces $45 Million Loan Agreement with Horizon Technology Finance Corporation to Refinance Existing Debt
16. Dezember 2022 06:01 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Evelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in Immunology
15. November 2022 16:01 ET
|
Evelo Biosciences, Inc.
Peer-reviewed article explains the immunology of the small intestinal axisCompany to hold a virtual Science Symposium on Wednesday, November 30, 2022, at 8:00am ET CAMBRIDGE, Mass., Nov. 15, 2022 ...
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights
14. November 2022 17:27 ET
|
Evelo Biosciences, Inc.
- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first...
Evelo Biosciences to Present at the 2022 Jefferies London Healthcare Conference
08. November 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting on...
Evelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
07. September 2022 01:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Evelo Biosciences Announces Grant of Inducement Award
01. September 2022 17:15 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Evelo Biosciences to Participate in Morgan Stanley 20th Annual Global Health Care Conference
01. September 2022 06:00 ET
|
Evelo Biosciences, Inc.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered medicines acting...
Evelo Biosciences Announces Succession Plan
11. August 2022 06:01 ET
|
Evelo Biosciences, Inc.
– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart for Chief Executive Officer search – ...
Evelo Biosciences Announces Second Quarter 2022 Financial Results and Business Highlights
11. August 2022 06:00 ET
|
Evelo Biosciences, Inc.
– Health authority feedback on registration trials for EDP1815 in psoriasis expected by year-end –– Two Phase 2 clinical read-outs with EDP1815 in atopic dermatitis expected in 1Q and 2Q 2023 –– Phase...